Join us for a TIDES USA Investor Recap Call – May 22, 2025, at 8 am ET

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending December 31, 2024

Company Overview

Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications.

Stock Snapshots

IR Contacts

Headquarters

Codexis, Inc.
200 Penobscot Drive
Redwood City, California 94063
T: 650-421-8100
media@codexis.com

Investor Relations

Codexis, Inc.
Carrie McKim
200 Penobscot Drive
Redwood City, CA 94063
United States
M: 650-421-8399
ir@codexis.com

Transfer Agent

EQ Shareowner Services
1110 Centre Pointe Curve
Suite 101
Mendota Heights, MN 55120-4100
T: 800-468-9716
https://www.shareowneronline.com